253 related articles for article (PubMed ID: 16782709)
1. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.
Baker DL; Fujiwara Y; Pigg KR; Tsukahara R; Kobayashi S; Murofushi H; Uchiyama A; Murakami-Murofushi K; Koh E; Bandle RW; Byun HS; Bittman R; Fan D; Murph M; Mills GB; Tigyi G
J Biol Chem; 2006 Aug; 281(32):22786-93. PubMed ID: 16782709
[TBL] [Abstract][Full Text] [Related]
2. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O
PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid.
Gupte R; Siddam A; Lu Y; Li W; Fujiwara Y; Panupinthu N; Pham TC; Baker DL; Parrill AL; Gotoh M; Murakami-Murofushi K; Kobayashi S; Mills GB; Tigyi G; Miller DD
Bioorg Med Chem Lett; 2010 Dec; 20(24):7525-8. PubMed ID: 21051230
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin: a protein with two faces.
Tania M; Khan MA; Zhang H; Li J; Song Y
Biochem Biophys Res Commun; 2010 Oct; 401(4):493-7. PubMed ID: 20888793
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases.
Gendaszewska-Darmach E
Acta Biochim Pol; 2008; 55(2):227-40. PubMed ID: 18560605
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid.
Uchiyama A; Mukai M; Fujiwara Y; Kobayashi S; Kawai N; Murofushi H; Inoue M; Enoki S; Tanaka Y; Niki T; Kobayashi T; Tigyi G; Murakami-Murofushi K
Biochim Biophys Acta; 2007 Jan; 1771(1):103-12. PubMed ID: 17123862
[TBL] [Abstract][Full Text] [Related]
7. Cyclic phosphatidic acid is produced by autotaxin in blood.
Tsuda S; Okudaira S; Moriya-Ito K; Shimamoto C; Tanaka M; Aoki J; Arai H; Murakami-Murofushi K; Kobayashi T
J Biol Chem; 2006 Sep; 281(36):26081-8. PubMed ID: 16837466
[TBL] [Abstract][Full Text] [Related]
8. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.
Altman MK; Gopal V; Jia W; Yu S; Hall H; Mills GB; McGinnis AC; Bartlett MG; Jiang G; Madan D; Prestwich GD; Xu Y; Davies MA; Murph MM
Mol Cancer; 2010 Jun; 9():140. PubMed ID: 20529378
[TBL] [Abstract][Full Text] [Related]
9. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of enantiopure 2-carba-cyclic phosphatidic acid and effects of its chirality on biological functions.
Nozaki E; Gotoh M; Hotta H; Hanazawa S; Kobayashi S; Murakami-Murofushi K
Biochim Biophys Acta; 2011 Apr; 1811(4):271-7. PubMed ID: 21277386
[TBL] [Abstract][Full Text] [Related]
11. 2-Carba-lysophosphatidic acid is a novel β-lysophosphatidic acid analogue with high potential for lysophosphatidic acid receptor activation and autotaxin inhibition.
Fukasawa K; Gotoh M; Uwamizu A; Hirokawa T; Ishikawa M; Shimizu Y; Yamamoto S; Iwasa K; Yoshikawa K; Aoki J; Murakami-Murofushi K
Sci Rep; 2021 Aug; 11(1):17360. PubMed ID: 34462512
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.
Tanaka M; Okudaira S; Kishi Y; Ohkawa R; Iseki S; Ota M; Noji S; Yatomi Y; Aoki J; Arai H
J Biol Chem; 2006 Sep; 281(35):25822-30. PubMed ID: 16829511
[TBL] [Abstract][Full Text] [Related]
13. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
14. Cyclic phosphatidic acid - a unique bioactive phospholipid.
Fujiwara Y
Biochim Biophys Acta; 2008 Sep; 1781(9):519-24. PubMed ID: 18554524
[TBL] [Abstract][Full Text] [Related]
15. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.
Hama K; Aoki J; Fukaya M; Kishi Y; Sakai T; Suzuki R; Ohta H; Yamori T; Watanabe M; Chun J; Arai H
J Biol Chem; 2004 Apr; 279(17):17634-9. PubMed ID: 14744855
[TBL] [Abstract][Full Text] [Related]
17. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.
Umezu-Goto M; Kishi Y; Taira A; Hama K; Dohmae N; Takio K; Yamori T; Mills GB; Inoue K; Aoki J; Arai H
J Cell Biol; 2002 Jul; 158(2):227-33. PubMed ID: 12119361
[TBL] [Abstract][Full Text] [Related]
18. Crystallization and preliminary X-ray crystallographic analysis of human autotaxin.
Inoue K; Tanaka N; Haga A; Yamasaki K; Umeda T; Kusakabe Y; Sakamoto Y; Nonaka T; Deyashiki Y; Nakamura KT
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Apr; 67(Pt 4):450-3. PubMed ID: 21505238
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
van Meeteren LA; Ruurs P; Christodoulou E; Goding JW; Takakusa H; Kikuchi K; Perrakis A; Nagano T; Moolenaar WH
J Biol Chem; 2005 Jun; 280(22):21155-61. PubMed ID: 15769751
[TBL] [Abstract][Full Text] [Related]
20. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
